Fenbendazole + cancer: 3 patients, 3 remissions + word on Dr. William Makis (update #194) CORRECTED!

Summary

The video discusses the use of veterinary-grade medications, particularly fenbendazole, by cancer patients as a self-treatment method. The narrator highlights three case studies where patients with advanced cancer achieved significant improvements or complete remissions after using fenbendazole along with other supplements. The paper, co-authored by Dr. William Makis, calls for clinical trials to better understand the drug’s effects on human cancer patients. The video also explores the potential mechanisms of fenbendazole’s action and the need for more research into unconventional cancer treatments.

Takeaways

• 😀 Veterinary-grade fenbendazole, typically used for dogs, is being explored as a potential treatment for cancer, despite not being approved for human use.
• 😀 The transcript discusses three successful case studies where advanced cancer patients self-medicated with fenbendazole, leading to remission or halted disease progression.
• 😀 The first case is a woman with stage 4 breast cancer who achieved complete remission after self-medicating with fenbendazole and supplements.
• 😀 The second case involves a man with stage 4 prostate cancer whose cancer stopped spreading after using fenbendazole alongside other supplements like vitamin D and curcumin.
• 😀 The third case is a man with advanced melanoma who achieved full remission after self-medicating with fenbendazole while waiting for prescribed immunotherapy.
• 😀 While the success stories are compelling, the paper stresses the need for further scientific validation through clinical trials to assess the safety and efficacy of fenbendazole for cancer treatment.
• 😀 The speaker highlights the importance of doctors documenting and publishing successful patient stories, even if the treatments are not officially approved, to trigger further research and clinical trials.
• 😀 Fenbendazole is suspected to work by disrupting microtubules in cells, causing cancer cells to self-destruct, as well as by promoting mitochondrial dysfunction and inhibiting angiogenesis (the growth of new blood vessels).
• 😀 The speaker suggests that fenbendazole could interfere with cancer cells’ ability to use glucose and glutamine for energy, which are vital for tumor growth.
• 😀 A major point of the discussion is the ethical responsibility of doctors to consider and explore non-traditional treatments when patients report success with them, even if the treatments are unconventional or off-label.
• 😀 Despite skepticism, the speaker suggests that the growing interest in alternative cancer treatments like fenbendazole could eventually lead to clinical trials and acceptance if enough documented cases are collected and studied.

Q & A

What is Fenbendazole, and why is it significant in cancer treatment according to the transcript?

Fenbendazole is a veterinary-grade medication typically used for treating parasites in animals, particularly dogs. Its significance in cancer treatment, as discussed in the transcript, lies in its potential to interfere with cancer cell mechanisms, such as inhibiting microtubule function, inducing mitochondrial dysfunction, and promoting tumor cell apoptosis. Despite its lack of approval for human use, some cancer patients have reportedly self-medicated with it, showing successful outcomes.

Why is Fenbendazole not approved for human use, and how does this affect its application in cancer treatment?

Fenbendazole is not approved for human use because it has only been tested and approved for veterinary applications, specifically for treating parasites in animals. Its use in cancer treatment is controversial due to the lack of clinical trials confirming its safety and efficacy in humans. The transcript emphasizes that while some patients have reported success, self-medicating with such an unapproved drug can be risky without professional oversight and proper research.

What is the main argument made by the authors of the paper about self-medicating with Fenbendazole?

The main argument made by the authors is that self-medication with unapproved drugs like Fenbendazole can be dangerous, as the proper dosages and mechanisms of action are not well understood in humans. They call for clinical trials to investigate its potential as a cancer treatment, emphasizing that more research is necessary to determine if and how it might work for human patients.

Who is Dr. William Makis, and why is he mentioned in the transcript?

Dr. William Makis is a controversial figure in oncology known for treating cancer patients with unconventional methods, including using medications like Ivermectin and Fenbendazole. He is mentioned because he co-authored the paper discussed in the transcript, which reports on patients using veterinary-grade medications to self-medicate for advanced cancer. His approach has sparked both interest and criticism in the medical community.

What were the results of the three cancer patients who self-medicated with Fenbendazole?

The three cancer patients reported varying degrees of success. Case 1 involved an 83-year-old woman with stage 4 breast cancer who experienced complete remission after using Fenbendazole. Case 2 involved a 75-year-old man with stage 4 prostate cancer who halted metastasis after self-medicating with Fenbendazole. Case 3 involved a man in his 60s with stage 3 melanoma, who achieved complete remission after using Fenbendazole along with other supplements.

What are the potential mechanisms by which Fenbendazole might work against cancer, as described in the transcript?

The potential mechanisms by which Fenbendazole may fight cancer include interfering with microtubule function, which can trigger cell death (apoptosis); inducing mitochondrial dysfunction, leading to cancer cell suicide; promoting the activity of the p53 tumor suppressor protein; inhibiting angiogenesis (the formation of new blood vessels for tumors); and disrupting the cancer cells' ability to use glucose and glutamine for energy.

What role do vitamins play in the cancer treatment regimens mentioned in the transcript?

Vitamins were commonly used alongside Fenbendazole in the cancer treatment regimens of the patients discussed. In all three cases, patients supplemented with Vitamin D, and in some cases, other vitamins like Vitamin K2, magnesium, melatonin, and curcumin. These vitamins are believed to support overall health and possibly enhance the effectiveness of the self-medication approach, although they are not the primary treatments.

Why does the transcript mention that Fenbendazole could be a threat to the pharmaceutical industry?

Fenbendazole could be seen as a threat to the pharmaceutical industry because it is a low-cost, readily available drug for veterinary use. If it proves effective as a cancer treatment, it could undermine the profitability of expensive cancer medications, especially if it is used as part of a combination therapy that does not rely on costly standalone drugs.

What is the transcript's stance on the need for clinical trials regarding Fenbendazole?

The transcript strongly advocates for the need for clinical trials to test Fenbendazole's effectiveness in treating cancer. While the success stories of patients who self-medicated are compelling, the transcript stresses that controlled, high-quality clinical trials are essential to understand the drug's safety, optimal dosage, and overall efficacy in humans.

How does the transcript address the concerns of oncologists regarding the use of veterinary medications like Fenbendazole?

The transcript acknowledges that oncologists would naturally advise against using veterinary medications like Fenbendazole, as they are not approved for human use and could be dangerous. However, it argues that if patients report positive outcomes from self-medicating, doctors should consider publishing such case studies to encourage further research. The transcript highlights the need for clinical trials to explore these unapproved treatments, even if they are controversial.